SRR2772780
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.400
- COMPLEMENT+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
- TGF_BETA_SIGNALING+0.400
- UV_RESPONSE_DN+0.400
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MTORC1_SIGNALING-0.400
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- DNA_REPAIR-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- GLYCOLYSIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579817 | — | A | 0.933 |
| 2 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.913 |
| 3 | d552ba81-1140-4ab6-a14c-659c07e494d0 | — | — | 0.911 |
| 4 | SRR1797302 | — | cohortMD2 | 0.898 |
| 5 | MDT-AP-2743 | Med | Medulloblastoma | 0.897 |
| 6 | DRR168604 | — | — | 0.895 |
| 7 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.893 |
| 8 | SRR8518425 | — | A | 0.890 |
| 9 | MDT-AP-2936 | Med | Medulloblastoma | 0.890 |
| 10 | TCGA-46-3766-01A-01R-0980-07 | — | cohortSQ1 | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |